Valneva (NASDAQ:VALN) Shares Gap Up to $7.95

Valneva SE (NASDAQ:VALN) gapped up before the market opened on Tuesday . The stock had previously closed at $7.95, but opened at $8.22. Valneva shares last traded at $8.22, with a volume of 485 shares.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Guggenheim decreased their target price on shares of Valneva from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, March 22nd. HC Wainwright restated a “buy” rating and issued a $26.00 price objective on shares of Valneva in a report on Friday, May 31st.

Valneva Trading Up 3.4 %

The company has a fifty day moving average of $8.16 and a 200-day moving average of $8.66. The company has a quick ratio of 2.22, a current ratio of 2.64 and a debt-to-equity ratio of 0.84.

Valneva (NASDAQ:VALN) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.12. Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%. The company had revenue of $35.56 million for the quarter, compared to analyst estimates of $95.80 million. On average, research analysts expect that Valneva SE will post -0.56 EPS for the current year.

Hedge Funds Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. lifted its stake in shares of Valneva SE (NASDAQ:VALN) by 2.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 354,361 shares of the company’s stock after buying an additional 9,361 shares during the quarter. General American Investors Co. Inc. owned approximately 0.51% of Valneva worth $2,831,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.